Lumito AB expands SCIZYS access through partnership with CRO Aurevia
Sweden's Lumito AB signed a collaboration with CRO Aurevia to offer its SCIZYS tissue analysis technology to drug developers and clinical researchers.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swedish company Lumito AB (publ) has entered a collaboration with contract research organization Aurevia (CRO). The partnership gives its SCIZYS tissue analysis technology an additional route to customers in drug development and clinical research.
According to TradingView, which cites the original press release, SCIZYS is already part of Aurevia's offering, and early discussions with potential clients and seminar participation have begun. The company is focusing on biomarker tissue analysis, a area where demand is rising in oncology research.
why it matters
The news is at an early stage and has limited market impact, since it reflects a commercial step by a small company. Signed contracts, project revenue and publications showing real-world uptake would matter more for judging the partnership's significance.
tags
instruments
sources
- Lumito AB (publ) (LUMITO) Partners With CRO Aurevia to Expand SCIZYS Access — TradingView, 22 October 2026 at 07:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗